Low serum levels of interleukin 35 in patients with rheumatoid arthritis

Tohoku Journal of Experimental Medicine

Volumn 237, Issue 2, 2015, Pages 77-82

  Ning, Xingwang ^a   Jian, Zijuan ^b   Wang, Wei ^b  

^a HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Autoimmune disease; Cytokine; Inflammation; Interleukin 35; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 35; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADULT; AGE; ARTICLE; BONE EROSION; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; AGED; AGING; BLOOD; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; REFERENCE VALUE; SEXUAL DEVELOPMENT;

AGED; AGING; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; INTERLEUKINS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PEPTIDES, CYCLIC; REFERENCE VALUES; RHEUMATOID FACTOR; SEX CHARACTERISTICS;

EID: 84941643421     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.237.77     Document Type: Article

References (31)

1. Alghasham, A. & Rasheed, Z. (2014) Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity, 47, 77-94.
2. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., Medsger, T.A. Jr., Mitchell, D.M., Neustadt, D.H., Pinals, R.S., Schaller, J.G., et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 31, 315-324.
3. Astry, B., Harberts, E. & Moudgil, K.D. (2011) A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J. Interferon Cytokine Res., 31, 927-940.
4. Bessis, N. & Boissier, M.C. (2001) Novel pro-inflammatory interleukins: potential therapeutic targets in rheumatoid arthritis. Joint Bone Spine, 68, 477-481.
5. Bobbio-Pallavicini, F., Alpini, C., Caporali, R., Avalle, S., Bugatti, S. & Montecucco, C. (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther., 6, R264-272.
6. Burska, A., Boissinot, M. & Ponchel, F. (2014) Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm., 2014, 545493.
7. Clavel, G., Thiolat, A. & Boissier, M.C. (2013) Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine, 80, 449-453.
8. Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S. & Vignali, D.A. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 450, 566-569.
9. Devergne, O., Birkenbach, M. & Kieff, E. (1997) Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci.USA, 94, 12041-12046.
10. Gabay, C. & McInnes, I.B. (2009) The biological and clinical importance of the ‘new generation’ cytokines in rheumatic diseases. Arthritis Res. Ther., 11, 230.
11. Gee, K., Guzzo, C., Che Mat, N.F., Ma, W. & Kumar, A. (2009) The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm. Allergy Drug Targets, 8, 40-52.
12. Kochetkova, I., Golden, S., Holderness, K., Callis, G. & Pascual, D.W. (2010) IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol., 184, 7144-7153.
13. Miossec, P., Korn, T. & Kuchroo, V.K. (2009) Interleukin-17 and type 17 helper T cells. N. Engl. J. Med., 361, 888-898.
14. Nakano, S., Morimoto, S., Suzuki, S., Tsushima, H., Yamanaka, K., Sekigawa, I. & Takasaki, Y. (2015) Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford), 54, 1498-1506.
15. Niedbala, W., Wei, X.Q., Cai, B., Hueber, A.J., Leung, B.P., McInnes, I.B. & Liew, F.Y. (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol., 37, 3021-3029.
16. Ogata, Y., Kukita, A., Kukita, T., Komine, M., Miyahara, A., Miyazaki, S. & Kohashi, O. (1999) A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J. Immunol., 162, 2754-2760.
17. Ouyang, H., Shi, Y.B., Liu, Z.C., Wang, Z., Feng, S., Kong, S.M. & Lu, Y. (2014) Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am. J. Med. Sci., 348, 156-161.
18. Pope, R.M. & Shahrara, S. (2013) Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat. Rev. Rheumatol., 9, 252-256.
19. Qiu, F., Song, L., Yang, N. & Li, X. (2013) Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus, 22, 1011-1016.
20. Schett, G. & Gravallese, E. (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol., 8, 656-664.
21. Schett, G., Stach, C., Zwerina, J., Voll, R. & Manger, B. (2008) How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum., 58, 2936-2948.
22. Shen, P., Roch, T., Lampropoulou, V., O’Connor, R.A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V.D., Jaimes, Y., Daridon, C., Li, R., Jouneau, L., Boudinot, P., Wilantri, S., Sakwa, I., et al. (2014) IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 507, 366-370.
23. Smolen, J.S. & Maini, R.N. (2006) Interleukin-6: a new therapeutic target. Arthritis Res. Ther., 8 Suppl 2, S5.
24. Striz, I., Brabcova, E., Kolesar, L. & Sekerkova, A. (2014) Cytokine networking of innate immunity cells: a potential target of therapy. Clin. Sci., 126, 593-612.
25. Thiolat, A., Denys, A., Petit, M., Biton, J., Lemeiter, D., Herve, R., Lutomski, D., Boissier, M.C. & Bessis, N. (2014) Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine, 69, 87-93.
26. Turk, S.A., van Beers-Tas, M.H. & van Schaardenburg, D. (2014) Prediction of future rheumatoid arthritis. Rheum. Dis. Clin. North Am., 40, 753-770.
27. van Boekel, M.A., Vossenaar, E.R., van den Hoogen, F.H. & van Venrooij, W.J. (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res., 4, 87-93.
28. van den Berg, W.B. & McInnes, I.B. (2013) Th17 cells and IL-17 a—focus on immunopathogenesis and immunotherapeutics. Semin. Arthritis Rheum., 43, 158-170.
29. van Gestel, A.M., Haagsma, C.J. & van Riel, P.L. (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum., 41, 1845-1850.
30. Wang, W., Jian, Z., Guo, J. & Ning, X. (2014) Increased levels of serum myeloperoxidase in patients with active rheumatoid arthritis. Life Sci., 117, 19-23.
31. Wright, H.L., Moots, R.J. & Edwards, S.W. (2014) The multifactorial role of neutrophils in rheumatoid arthritis. Nat. Rev. Rheumatol., 10, 593-601.